and congrats to anyone who was able to accumulate MITI below 5 last week. We may never ever see that price again...that was a rare gift due to most likely selling of SPY index funds that day. But with ASH just around the corner and the long term viability of this company all but assured, MITI is one of those rare gems in biotech. It has a real chance of making news spalsh in December, but in Phase III if it is half as effective (the numbers will be higher), this is close to cancer cure than anyone has ever seen. Eventual market for ALL, NHL and many other B-cell lymphoma will be huge, especially if this can be used (and will be approved) as first line treatment, you are talking about a company of 10B or more in 2-3 years! Much more than DNDN can ever hope to...I hope the fireworks begin this december. I also think Astra (Medimmune) will opt in right after Phase II data in ASH.